# Cypherpunk Technologies Inc.: financial statements, quarterly

CYPH · Nasdaq · CIK 1509745 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cyph.md) · [Financials](/companies/cyph/financials.md) · [Filings](/companies/cyph/filings.md) · [Insiders](/companies/cyph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cyph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [11.5](/filings/0001410578-24-001913.md) | [11.7 d](/filings/0001410578-25-000454.md) | [11.3](/filings/0001410578-25-001204.md) | [17.9](/filings/0001410578-25-001774.md) | [14.9](/filings/0001104659-25-109827.md) | [13.1 d](/filings/0001104659-26-028566.md) | [12.9](/filings/0001104659-26-060662.md) | [10.5](/filings/0001104659-26-094449.md) | [1.2](/filings/0001104659-25-109827.md) | [1.0 d](/filings/0001104659-26-028566.md) | [0.2](/filings/0001104659-26-060662.md) | [0.2](/filings/0001104659-26-094449.md) |
| Operating income | $m | [(14.8)](/filings/0001410578-24-001913.md) | [(14.8) d](/filings/0001410578-25-000454.md) | [(14.8)](/filings/0001410578-25-001204.md) | [(21.3)](/filings/0001410578-25-001774.md) | [(17.9)](/filings/0001104659-25-109827.md) | [(16.1) d](/filings/0001104659-26-028566.md) | [(15.9)](/filings/0001104659-26-060662.md) | [(16.9)](/filings/0001104659-26-094449.md) | [(3.2)](/filings/0001104659-25-109827.md) | [(5.1) d](/filings/0001104659-26-028566.md) | [(4.8)](/filings/0001104659-26-060662.md) | [(4.7)](/filings/0001104659-26-094449.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-060662.md) | [0.0](/filings/0001104659-26-094449.md) | [0.0](/filings/0001104659-25-109827.md) | [0.0 d](/filings/0001104659-26-028566.md) | [0.0](/filings/0001104659-26-060662.md) | [0.0](/filings/0001104659-26-094449.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | [0.7](/filings/0001104659-25-109827.md) | [(0.1) d](/filings/0001104659-26-028566.md) | not reported | not reported | [0.2](/filings/0001104659-25-109827.md) | [5.1 d](/filings/0001104659-26-028566.md) | [(5.1)](/filings/0001104659-26-060662.md) | [2.0](/filings/0001104659-26-094449.md) |
| Net income | $m | [(13.7)](/filings/0001410578-24-001913.md) | [(12.5) d](/filings/0001410578-25-000454.md) | [(13.8)](/filings/0001410578-25-001204.md) | [(20.1)](/filings/0001410578-25-001774.md) | [(18.2)](/filings/0001104659-25-109827.md) | [(15.4) d](/filings/0001104659-26-028566.md) | [(15.4)](/filings/0001104659-26-060662.md) | [(16.6)](/filings/0001104659-26-094449.md) | [(3.3)](/filings/0001104659-25-109827.md) | [40.2 d](/filings/0001104659-26-028566.md) | [(77.2)](/filings/0001104659-26-060662.md) | [39.4](/filings/0001104659-26-094449.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0001410578-24-001913.md) | not reported | [(0.51)](/filings/0001410578-25-001204.md) | [(0.52)](/filings/0001410578-25-001774.md) | [(0.44)](/filings/0001104659-25-109827.md) | not reported | [(0.37)](/filings/0001104659-26-060662.md) | [(0.40)](/filings/0001104659-26-094449.md) | [(0.08)](/filings/0001104659-25-109827.md) | not reported | [(0.46)](/filings/0001104659-26-060662.md) | [0.18](/filings/0001104659-26-094449.md) |
| Basic EPS | $ per share | [(0.51)](/filings/0001410578-24-001913.md) | not reported | [(0.51)](/filings/0001410578-25-001204.md) | [(0.52)](/filings/0001410578-25-001774.md) | [(0.44)](/filings/0001104659-25-109827.md) | not reported | [(0.37)](/filings/0001104659-26-060662.md) | [(0.40)](/filings/0001104659-26-094449.md) | [(0.08)](/filings/0001104659-25-109827.md) | not reported | [(0.46)](/filings/0001104659-26-060662.md) | [0.21](/filings/0001104659-26-094449.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [80.7](/filings/0001410578-23-002343.md) | [70.6](/filings/0001410578-25-000454.md) | [54.9](/filings/0001410578-24-000748.md) | [78.5](/filings/0001410578-24-001284.md) | [62.8](/filings/0001410578-24-001913.md) | [47.2](/filings/0001104659-26-028566.md) | [32.7](/filings/0001410578-25-001204.md) | [18.1](/filings/0001410578-25-001774.md) | [9.7](/filings/0001104659-25-109827.md) | [14.0](/filings/0001104659-26-094449.md) | [6.7](/filings/0001104659-26-060662.md) | [7.6](/filings/0001104659-26-094449.md) |
| Current assets | $m | [81.8](/filings/0001410578-23-002343.md) | [71.6](/filings/0001410578-25-000454.md) | [56.2](/filings/0001410578-24-000748.md) | [79.6](/filings/0001410578-24-001284.md) | [63.8](/filings/0001410578-24-001913.md) | [48.0](/filings/0001104659-26-028566.md) | [33.9](/filings/0001410578-25-001204.md) | [19.2](/filings/0001410578-25-001774.md) | [10.5](/filings/0001104659-25-109827.md) | [162](/filings/0001104659-26-094449.md) | [81.9](/filings/0001104659-26-060662.md) | [138](/filings/0001104659-26-094449.md) |
| Total assets | $m | [83.0](/filings/0001410578-23-002343.md) | [72.8](/filings/0001410578-25-000454.md) | [58.0](/filings/0001410578-24-000748.md) | [81.4](/filings/0001410578-24-001284.md) | [65.0](/filings/0001410578-24-001913.md) | [49.1](/filings/0001104659-26-028566.md) | [34.9](/filings/0001410578-25-001204.md) | [20.0](/filings/0001410578-25-001774.md) | [11.4](/filings/0001104659-25-109827.md) | [163](/filings/0001104659-26-094449.md) | [87.4](/filings/0001104659-26-060662.md) | [143](/filings/0001104659-26-094449.md) |
| Current liabilities | $m | [11.0](/filings/0001410578-23-002343.md) | [12.7](/filings/0001410578-25-000454.md) | [10.4](/filings/0001410578-24-000748.md) | [15.6](/filings/0001410578-24-001284.md) | [16.1](/filings/0001410578-24-001913.md) | [14.1](/filings/0001104659-26-028566.md) | [14.0](/filings/0001410578-25-001204.md) | [14.3](/filings/0001410578-25-001774.md) | [8.7](/filings/0001104659-25-109827.md) | [4.6](/filings/0001104659-26-094449.md) | [3.0](/filings/0001104659-26-060662.md) | [1.7](/filings/0001104659-26-094449.md) |
| Total liabilities | $m | [11.0](/filings/0001410578-23-002343.md) | [12.7](/filings/0001410578-24-001913.md) | [10.6](/filings/0001410578-24-000748.md) | [15.6](/filings/0001410578-24-001284.md) | [16.1](/filings/0001410578-24-001913.md) | [14.1](/filings/0001104659-26-028566.md) | not reported | not reported | [8.7](/filings/0001104659-25-109827.md) | [9.7](/filings/0001104659-26-094449.md) | [3.0](/filings/0001104659-26-060662.md) | [3.7](/filings/0001104659-26-094449.md) |
| Shareholders' equity | $m | [72.0](/filings/0001410578-24-001913.md) | [60.1](/filings/0001104659-26-028566.md) | [47.4](/filings/0001410578-25-001774.md) | [65.8](/filings/0001104659-25-109827.md) | [49.0](/filings/0001104659-25-109827.md) | [35.0](/filings/0001104659-26-094449.md) | [20.8](/filings/0001104659-26-094449.md) | [5.7](/filings/0001104659-26-094449.md) | [2.7](/filings/0001104659-25-109827.md) | [154](/filings/0001104659-26-094449.md) | [84.4](/filings/0001104659-26-094449.md) | [139](/filings/0001104659-26-094449.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.5) d](/filings/0001410578-24-001913.md) | [(10.4) d](/filings/0001410578-25-000454.md) | [(15.5)](/filings/0001410578-25-001204.md) | [(13.7) d](/filings/0001410578-25-001774.md) | [(15.6) d](/filings/0001104659-25-109827.md) | [(15.5) d](/filings/0001104659-26-028566.md) | [(14.5)](/filings/0001104659-26-060662.md) | [(14.5) d](/filings/0001104659-26-094449.md) | [(8.3) d](/filings/0001104659-25-109827.md) | [(6.6) d](/filings/0001104659-26-028566.md) | [(3.4)](/filings/0001104659-26-060662.md) | [(2.7) d](/filings/0001104659-26-094449.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.3](/filings/0001410578-23-002343.md) | [12.9](/filings/0001410578-24-000748.md) | [14.7](/filings/0001410578-24-001284.md) | [27.0](/filings/0001410578-24-001913.md) | [27.0](/filings/0001410578-25-001204.md) | [39.1](/filings/0001410578-25-001774.md) | [41.2](/filings/0001104659-25-109827.md) | [41.3](/filings/0001104659-26-060662.md) | [41.4](/filings/0001104659-26-094449.md) | [41.4](/filings/0001104659-25-109827.md) | [168](/filings/0001104659-26-060662.md) | [217](/filings/0001104659-26-094449.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 107,764,382 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001104659-26-094449.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.